Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

My previous session
Most popular
Real-time Quote. Real-time Cboe BZX - 08/16 09:45:29 pm
68.845 USD   +2.19%
06:02pPERRIGO : Expands OTC Growth Strategy with Rx-To-OTC Switch Licensin..
08/15DOW MOVERS : Cat, mrk
08/15MERCK AND : Foundation Supports New Programs to Improve Care for Alz..
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
06/22/2012 | 07:32pm CEST
   By Jon Kamp 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at jon.kamp@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
06:18pAGILENT TECHNOLOGIES : Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma
06:02pPERRIGO : Expands OTC Growth Strategy with Rx-To-OTC Switch Licensing For Nasone..
08/15DOW MOVERS : Cat, mrk
08/15MERCK AND : Foundation Supports New Programs to Improve Care for Alzheimer&rsquo..
08/13Roundup cancer verdict sends Bayer shares sliding
08/13Roundup cancer verdict sends Bayer shares sliding
08/10MERCK AND : Head of Human Resources Mirian M. Graddick-Weir to Retire, Steven C...
08/09EISAI : and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVI..
08/09MERCK AND : - Selumetinib Granted Orphan Designation in Europe for Neurofibromat..
08/09MERCK AND : AstraZeneca - Selumetinib granted orphan designation in Europe for n..
More news
News from SeekingAlpha
11:52aThe Battle For Best-In-Class In ATTR Has Begun 
08/15Agenus earns second $4M milestone payment from Merck 
08/15More Dow Gains Ahead For Caterpillar, DowDuPont, Goldman, Chevron, And Boeing.. 
08/14Eton Pharmaceuticals Files For U.S. IPO 
08/13TherapeuticsMD Announces FDA Approval For Year-Round Contraceptive Ring 
Financials ($)
Sales 2018 42 401 M
EBIT 2018 13 777 M
Net income 2018 7 016 M
Debt 2018 15 241 M
Yield 2018 2,89%
P/E ratio 2018 26,10
P/E ratio 2019 17,59
EV / Sales 2018 4,53x
EV / Sales 2019 4,32x
Capitalization 177 B
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 70,7 $
Spread / Average Target 4,9%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY19.73%176 752
JOHNSON & JOHNSON-7.31%347 417
PFIZER13.64%238 136
NOVARTIS-1.87%207 488
ROCHE HOLDING LTD.-3.75%206 696
AMGEN12.57%126 710